Twist Bioscience Corporation (NASDAQ:TWST) Given Average Rating of “Moderate Buy” by Analysts

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $45.8750.

Several equities research analysts recently weighed in on the stock. Evercore increased their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 3rd. Barclays boosted their price objective on Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Finally, Stephens started coverage on shares of Twist Bioscience in a report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price objective on the stock.

Insider Activity at Twist Bioscience

In related news, SVP Paula Green sold 1,194 shares of Twist Bioscience stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $46.58, for a total transaction of $55,616.52. Following the sale, the senior vice president directly owned 165,445 shares in the company, valued at $7,706,428.10. The trade was a 0.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 5,001 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $46.58, for a total transaction of $232,946.58. Following the completion of the transaction, the chief executive officer owned 869,312 shares of the company’s stock, valued at $40,492,552.96. This represents a 0.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 24,609 shares of company stock valued at $1,065,501. Company insiders own 3.08% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently modified their holdings of the stock. Quarry LP acquired a new stake in shares of Twist Bioscience during the third quarter worth approximately $28,000. Strategic Advocates LLC boosted its stake in shares of Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after buying an additional 906 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of Twist Bioscience by 70.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after acquiring an additional 442 shares in the last quarter. SBI Securities Co. Ltd. increased its stake in shares of Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after acquiring an additional 571 shares during the last quarter. Finally, Leonteq Securities AG acquired a new stake in Twist Bioscience during the fourth quarter valued at $48,000.

Twist Bioscience Stock Up 1.2%

NASDAQ:TWST opened at $49.64 on Thursday. The stock has a 50-day simple moving average of $37.99 and a 200 day simple moving average of $32.29. Twist Bioscience has a one year low of $23.30 and a one year high of $51.00. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of -38.78 and a beta of 2.24. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The firm had revenue of $103.70 million during the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The company’s revenue for the quarter was up 16.9% on a year-over-year basis. Sell-side analysts predict that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.